The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.

Inclusion Criteria:

• Active Eosinophilic esophagitis (EoE) with histologic evidence as a peak count of ≥ 15 eosinophils per higher-power field at any 2 levels of the esophagus
• Previously received an adequate trial of proton-pump inhibitor medication that did not provide complete response to EoE
• EoE symptoms documented in daily diary during the screening period

Exclusion Criteria:

• On a regimen of therapeutic anticoagulation
• Demonstrates evidence of immunosuppression or is receiving systemic immunosuppressive or immunomodulating drugs
• Currently receiving a high potency topical corticosteroid for dermatologic use

Other protocol-defined inclusion/exclusion criteria apply